Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Drew Newhoff

General Practice Albuquerque, NM Medical Doctor

NPI 1760757199 CMS profile 1238958

4304 Carlisle Blvd Ne, Albuquerque, NM 87107

Open in the dashboard

General payments

$16,724

113 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Drew Newhoff of Albuquerque, NM is reported in the CMS Open Payments database as having received $16,724 across 113 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $479 14
2024 General $1,331 19
2023 General $458 14
2022 General $1,621 16
2021 General $435 10
2020 General $7,743 16
2019 General $4,658 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Drew Newhoff
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Drew Newhoff were reported at $479. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Drew Newhoff General Practice median Middle half National median
2019 $4,658 $107 $37–$285 $163
2020 $7,743 $75 $25–$213 $114
2021 $435 $93 $30–$272 $132
2022 $1,621 $103 $36–$279 $149
2023 $458 $106 $34–$276 $160
2024 $1,331 $114 $39–$290 $164
2025 $479 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $13,803 68 payments
  2. Gemini Mountain Medical, LLC $1,801 4 payments
  3. Electronic Waveform Lab, Inc. $494 25 payments
  4. DePuy Synthes Sales Inc. $219 7 payments
  5. Skeletal Dynamics Inc $140 1 payment
  6. Acumed LLC $100 1 payment
  7. Arthrex, Inc. $87 3 payments
  8. Stryker Corporation $53 2 payments
  9. Zimmer Biomet Holdings, Inc. $25 1 payment
  10. Orthofix Medical, Inc. $2 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,513 1 payment
  2. Food and Beverage $3,981 102 payments
  3. Consulting Fee $3,488 3 payments
  4. Travel and Lodging $2,544 6 payments
  5. Education $1,200 1 payment
Products named General payments · program years 2019–2025
  1. EVOS Trauma Plates, Screws, and Nails $10,821 17 payments
  2. PROCISE Tonsil $1,129 2 payments
  3. DERMAL WOUND $1,129 2 payments
  4. Journey II $1,129 2 payments
  5. HEALICOIL PK Hip $1,129 2 payments
  6. TRIGEN InterTAN $556 4 payments
  7. Journey II XR $508 1 payment
  8. Ascension $320 2 payments
  9. Taylor Spatial Frame $264 1 payment
  10. EVOS Trauma Plates, Screws, and Nails $249 4 payments
  11. Other $2,546 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

264

Median for Hand Surgery: 118

Drug cost

$1,517

Median for Hand Surgery: $615

Branded share of claims

0%

Median for Hand Surgery: 34.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 212 $1,031
Meloxicam Generic 15 $147
Gabapentin Generic 13 $141
Ibuprofen Generic 13 $121
Cephalexin Generic 11 $77

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,399 Part D prescribers listed as Hand Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 99 billing codes

Paid by Medicare

$154,011

Of which drugs: $5,643

Medicare patients

530

Average age 73

Services billed

2,581

331 women, 199 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 70%
High blood pressure 63%
Diabetes 26%
Depression 21%
Osteoporosis 20%
Chronic kidney disease 19%
Ischemic heart disease 18%
Atrial fibrillation 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 198 896 $600

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

113 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record